Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Idarubicin and Etoposide vs IV MAE for Consolidation in Older AML Patients
NCT00003602Phase 3Unknown
- Sponsor
- Riverside Haematology Group
- Start
- Mar 1998
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin, etoposide, mitoxantrone, cytarabine in acute myeloid leukemia (AML), sponsored by Riverside Haematology Group. Status: unknown.
02
Drugs
idarubicinetoposidemitoxantronecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003602.